3 October 2024
Latham & Watkins Advises Metsera in Strategic Collaboration With Amneal
Advising firms
Deal team
8 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Steve Chinowsky Lead | Latham & Watkins LLP | Partner | life sciences licensing | Not stated |
| Darryl Steensma | Latham & Watkins LLP | Counsel | life sciences licensing | Not stated |
| Mike Sweeney | Latham & Watkins LLP | Associate | life sciences licensing | Not stated |
| Steve Levine | Latham & Watkins LLP | Partner | real estate and project development | Not stated |
| Daniel Eyal | Latham & Watkins LLP | Associate | real estate and project development | Not stated |
| Peter Handrinos | Latham & Watkins LLP | Partner | corporate | Not stated |
| Kirk Switzer | Latham & Watkins LLP | Partner | tax | Not stated |
| Derek Gumm | Latham & Watkins LLP | Associate | tax | Not stated |
Stated terms
- Stated value
- Not stated
- What the figure measures
- Total transaction value
- Client
- Metsera, Inc.Joint venture party
- Counterparties
- Amneal Pharmaceuticals, Inc. (Joint venture party)